Skip to main content
CAPR
NASDAQ Life Sciences

FDA Extends Deramiocel PDUFA Date to November 22, 2026 After Major Amendment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.89
Mkt Cap
$365.694M
52W Low
$2.96
52W High
$40.37
52W Position info
133% above low
Off High info
83% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

CAPR has more than doubled off its 52-week low of $2.96.

Summary

FDA extended the Deramiocel PDUFA date by three months to November 22, 2026, after classifying Capricor's BLA amendment as major. The amendment includes 24-month HOPE-3 data supporting a refined upper limb function indication.


Key Events · Product Development and Regulatory · CAPR

  • PDUFA Date Extended to November 22, 2026

    FDA extended the Deramiocel BLA target action date from August 22, 2026 to November 22, 2026, a three-month delay.

  • Major Amendment Classification

    FDA classified Capricor's submission as a major amendment, which triggered the extended review period.

  • Refined Indication Focused on Upper Limb Function

    Capricor requested FDA review of 24-month HOPE-3 open-label extension data and additional analyses supporting a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3.

  • Negative Advisory Committee Vote Precedes Extension

    The extension follows the July 29, 2026 FDA advisory committee's 9-3 vote against deramiocel's effectiveness data for DMD-related heart disease.


Analysis · CAPR · Life Sciences

The FDA has pushed the Deramiocel BLA decision from August 22 to November 22, 2026, classifying Capricor's submission as a major amendment. This follows the July 29 advisory committee's 9-3 vote against the drug's effectiveness data. The extension gives Capricor three more months to convince the FDA that its 24-month HOPE-3 open-label data supports a refined indication focused on upper limb function. The delay is a double-edged sword: it keeps the approval path alive after a negative adcomm, but it also means no near-term revenue from Deramiocel and extends the company's cash burn. With $237.9M in cash as of Q2 and a $40.7M quarterly loss, the runway remains adequate but the regulatory uncertainty is now prolonged.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CAPR was trading at $6.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $365.7M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Nov 10, 2026, 5:25 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $9.32 info
Change: -$0.030 (-0.32%) info
Market Cap: $554.094M info
CAPR
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.10
Real-time Price: $9.32 info
Change: +$0.220 (+2%) info
Market Cap: $554.094M info
CAPR
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $9.32 info
Change: +$0.415 (+5%) info
Market Cap: $554.094M info
CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $9.32 info
Change: +$0.237 (+3%) info
Market Cap: $554.094M info
CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $9.32 info
Change: +$1.10 (+13%) info
Market Cap: $554.094M info